Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
Karen M. Fancher,(1,2) PharmD, BCOP, and Elizabeth J. Bunk,(1) PharmD
¹Duquesne University Mylan School of Pharmacy, Pittsburgh, Pennsylvania; ²University of Pittsburgh Medical Center Passavant, Pittsburgh, Pennsylvania
Authors’ disclosures of potential conflict of interest are found at the end of this article.
Karen M. Fancher, PharmD, BCOP, Duquesne University Mylan School of Pharmacy, 322 Bayer Building, 600 Forbes Avenue, Pittsburgh, PA 15232.
J Adv Pract Oncol 2016;7:542–547 |
doi: 10.6004/jadpro.2016.7.5.6 |
© 2016 Harborside Press®
For access to the full length article, please sign in